ストックスクリーナーアプリを入手
9.63
5.53%
0.505
アフターアワーズ：
9.81
0.18
+1.87%
前日終値:
$9.125
開ける：
$8.95
24時間の取引高:
64,236
Relative Volume:
0.24
時価総額：
$45.20M
収益：
-
当期純損益:
$-12.36M
株価収益率:
-3.1734
EPS:
-3.0346
ネットキャッシュフロー:
$-5.58M
1週間 パフォーマンス:
-1.13%
1か月 パフォーマンス:
-12.69%
6か月 パフォーマンス:
-31.02%
1年 パフォーマンス:
+13.29%
1日の値動き範囲:
$8.7173
$9.97
1週間の範囲:
$8.4801
$9.97
52週間の値動き範囲:
$6.34
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Compare INKT vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
9.63 | 42.83M | 0 | -12.36M | -5.58M | -3.0346 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc (INKT) 最新ニュース
What is the target price for MiNK Therapeutics Inc stock2026 Market Mood & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Weekly Trades: Is MiNK Therapeutics Inc a defensive stock2026 Big Picture & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Responsive Playbooks and the INKT Inflection - Stock Traders Daily
Death Cross: What is MiNK Therapeutics Incs revenue forecast2026 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
MiNK Therapeutics pediatric cancer breakthrough sparks stock rally - MSN
MiNK Therapeutics (INKT) officer Form 3 shows 40 common shares held - Stock Titan
Why is MiNK Therapeutics stock trading lower on Wednesday? - MSN
If You Invested $1,000 in Mink Therapeutics, Inc. (INKT) - Stock Titan
MiNK Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 6Q40 | US6036932019 - marketscreener.com
MiNK Therapeutics Appoints New Principal Financial Officer – SEC 8-K Filing Details and Company Information - Minichart
MiNK Therapeutics appoints new principal financial and accounting officers By Investing.com - Investing.com Australia
MiNK Therapeutics appoints new principal financial and accounting officers - Investing.com
MiNK Therapeutics Appoints New Principal Financial and Accounting Officers - TipRanks
Biopharmaceutical company MiNK Therapeutics, Inc. announces a significant personnel appointment - Bitget
MiNK Therapeutics (NASDAQ: INKT) names new financial leadership team - Stock Titan
Mink Therapeutics, Inc. Appoints Austin Charette as Principal Accounting Officer, Effective March 13, 2026 - marketscreener.com
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs - Investing News Network
Published on: 2026-03-17 21:54:50 - baoquankhu1.vn
Mink Therapeutics to report fourth quarter and full year 2025 financial results and highlight platform expansion across inkt cell therapy programs - marketscreener.com
MiNK Therapeutics to Report Q4 and Full Year 2025 Financial Results on March 31, 2026, Following Strategic Collaborations and Clinical Updates - Quiver Quantitative
MiNK’s pediatric cancer cell therapy pact brings funding, revenue upside - Stock Titan
Understanding the Setup: (INKT) and Scalable Risk - Stock Traders Daily
Mink Therapeutics Inc expected to post a loss of 82 cents a shareEarnings Preview - TradingView
Why Did INKT Stock Jump 30% Today? - Stocktwits
MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares - MarketBeat
MiNK Therapeutics (INKT) director Barbara Ryan sells 1,500 shares in open market - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? - Benzinga
Why did INKT stock surge 70% in pre-market today? - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MiNK Therapeutics Stock Gains Amid New Market Developments - StocksToTrade
MiNK Therapeutics jumps on pediatric cancer collaboration and non-dilutive funding news - Quiver Quantitative
Key Patent Dispute Hits INKT’s Financials - timothysykes.com
MiNK Therapeutics (INKT) Stock Rockets 80% on Pediatric Cancer Partnership with C-Further - parameter.io
MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock RallyMiNK Therapeutics (NASDAQ:INKT) - Benzinga
MiNK Therapeutics (INKT) Stock Rockets 80% Following Pediatric Cancer Partnership - Blockonomi
MiNK Therapeutics (INKT) Stock Surges 80% on C-Further Pediatric Cancer Deal - CoinCentral
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers - Investing News Network
Mink Therapeutics and C-Further Collaborate to Advance Prame-Targeted Inkt Cell Therapy for Pediatric Cancers - marketscreener.com
INKTMink Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
MiNK Therapeutics stock soars 80% on C-Further collaboration By Investing.com - Investing.com Canada
MiNK Therapeutics shares surged 70% in pre-market trading after the company announced that its partner C-Further received up to $1.1 million in funding to advance pediatric cancer cell therapy research. - Bitget
Why Did INKT Stock Surge 70% In Pre-Market Today? - Asianet Newsable
MiNK Therapeutics announces collaboration with C-Further to advance PRAME-targeted iNKT cell therapy - marketscreener.com
New off-the-shelf cell therapy targets aggressive childhood cancers - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Trading Up 1.7% – Time to Buy? - Defense World
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Bond Watch: What is MiNK Therapeutics Incs revenue forecast2026 Volume & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - BioSpace
MiNK Therapeutics (INKT) director sells 500 shares in open trades - Stock Titan
Mink Therapeutics Inc (INKT) 財務データ
収益
当期純利益
現金流量
EPS
0.04%
0.06%
大文字化:
|
ボリューム (24 時間):